1,721,111 research outputs found
Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study
No full textAbstract not availableMichele Baccarani; Brian J. Druker; Susan Branford; Dong-Wook Kim; Fabrizio Pane; Lidia Mongay; Manisha Mone; Christine-Elke Ortmann; Hagop M. Kantarjian; Jerald P. Radich; Timothy P. Hughes; Jorge E. Cortes; François Guilho
A Review of Mutation Analysis In the TOPS Trial of Standard Dose Versus High Dose IM In CML Suggests That Refinements to the ELN Recommendations for Mutation Screening May Be Appropriate
No full textPublished online October 12, 2015.Susan Branford, Hyun-Gyung Goh, Barbara Izzo, Lan Beppu, Christine-Elke Ortmann, Kamila Duniec, Yu Jin, Richard C. Woodman, Fabrizio Pane, Dong-Wook Kim, Jerald P. Radich, and Timothy P. Hugheshttp://ash.confex.com/ash/2010/webprogram/Paper31856.htm
Treatment Milestones in Chronic Myelogenous Leukemia: Stay the Course or Change Therapy?
No full text
Molecular Monitoring of Patients With Chronic Myeloid Leukemia: Clinical Examples From a Non-Trial Setting
No full text
Monitoring Molecular Response to Tyrosine Kinase Therapy in Chronic Myelogenous Leukemia
No full textThe dramatic decline in mortality rates in chronic myelogenous leukemia (CML) is a direct result of the advent of tyrosine kinase inhibitors (TKIs) and the dawning of the targeted era. Although many patients experience long-term benefits from imatinib or related agents, problems with resistance and tolerance dampen the outcomes for many others. During his presentation at the NCCN 19th Annual Conference, Dr. Jerald Radich reviewed the ever-expanding menu of TKIs for CML and shared his thoughts on resolving the clinical questions regarding when to start which drugs, how to sequence the drugs, and how best to decide when to change the therapeutic tack.</jats:p
- …
